Our ability to use preclinical models that recapitulate the human expression of CD40 and FcγRs has allowed us to prioritize the most biological rational approaches and which tumor types to focus on in future studies with 2141-V11, either alone or in combination with standard or novel therapies. The gene discussed is CD40; the disease is neoplasm.